Comparative Pharmacology
Head-to-head clinical analysis: LORATADINE REDIDOSE versus POLARAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORATADINE REDIDOSE versus POLARAMINE.
LORATADINE REDIDOSE vs POLARAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
10 mg orally once daily
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Category A/B
Category C
Antihistamine
Antihistamine